Tag - PharmaCyte

Feature

PharmaCyte’s Cell-in-a-Box encapsulation technology targeting cancer, diabetes

PharmaCyte Biotech (OTCQB:PMCB) is developing cellular therapies for its lead pancreatic cancer program and for diabetes that are based on a proprietary cellulose-based live cell encapsulation technology known as a Cell...

July 23, 2019

Developments

PharmaCyte and UTS creating advanced version of Melligen cells to treat diabetes

PharmaCyte Biotech (OTCQB:PMCB) entered into a new research agreement with the University of Technology Sydney (UTS) in Australia to create a new version of Melligen cells for the treatment of diabetes, with the...

July 22, 2019

Executive Moves

PharmaCyte appoints cellular expert, David Judd, to medical and SAB

David Judd PharmaCyte Biotech (OTCQB: PMCB) appointed David Judd to its medical and scientific advisory board. Mr. Judd has had over 30 years of experience in the research and development of cell culture materials and...

July 15, 2019

Tag - PharmaCyte

PharmaCyte’s Cell-in-a-Box encapsulation technology targeting cancer, diabetes

PharmaCyte and UTS creating advanced version of Melligen cells to treat diabetes

PharmaCyte appoints cellular expert, David Judd, to medical and SAB

General

More